Résztvevőt keres4. fázis

Secondary Prevention of VTE in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis

A legfontosabb adatok

Ki végzi: Ottawa Hospital Research Institute
Hol: Kanada2 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító: NCT06603870
Állapot: Toboroz
Fázis: 4. fázis
Résztvevők: 330 fő, tervezett
Kezdés: 2024. dec. 19.
Várható befejezés: 2029. okt.
A vizsgálat típusa: Beavatkozással járó
A vizsgált kezelések: Anticoagulation Therapy
A regiszteradat frissítve: 2026. szeptember 21.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with active cancer who had a blood clot in an arm vein linked to a catheter. They must have had blood-thinner treatment for at least 3 months.

Életkor: 18 years and older
Nem: All sexes
A betegség stádiuma: Active cancer: diagnosed or treated within 6 months, spread, returned or growing, on cancer treatment, or blood cancer not in complete remission. Localized non-melanoma skin cancer does not count. A confirmed catheter-related deep vein clot in the arm.
Korábbi kezelés: Must have had standard full-dose blood-thinner treatment for at least 3 months (LMWH lowered to 75% after the first month is allowed). Blood thinner must not have been stopped or lowered to a preventive dose for > 5 days before joining.

A részvétel fő kizáró okai

Active bleeding or other reasons blood thinners cannot be used
Other conditions needing ongoing full-dose blood thinners, such as atrial fibrillation or a mechanical heart valve
Cancer in remission and the central catheter already removed
Platelet count < 50 x 109/L or creatinine clearance < 30 ml/min
Life expectancy of less than 3 months

A regiszter feltételei, szó szerint

Mind a 12 feltétel megnézéseKevesebb

Ki vehet részt

Adult patients (≥ 18 years old) with active cancer, defined as cancer (other than localized non-melanoma skin cancer) diagnosed or treated within 6 months, or the presence of metastatic, recurrent, or progressive malignancy, ongoing anticancer therapy, or hematological malignancy not in complete remission
Objectively confirmed catheter-related upper extremity DVT and treated with any standard therapeutic anticoagulation (including LMWH dose reduction to 75% after the first month) for at least 3 months
Able and willing to provide informed consent

Ki nem vehet részt

Anticoagulation has been permanently stopped or reduced to prophylactic dose for > 5 days prior to enrollment for any reasons
Concomitant use of strong inhibitors or inducers of both cytochrome P450 3A4 and P-glycoprotein in patients who are prescribed a direct oral anticoagulant
Cancer is in remission and CVC is removed prior to enrollment
Requirement of dual antiplatelet therapies
Active bleeding or other reasons for which anticoagulation is contraindicated
Other indications requiring ongoing therapeutic dose of anticoagulation as deemed necessary by treating physicians (such as atrial fibrillation, mechanical heart valve, etc.)
Platelet count < 50 x 109/L or creatinine clearance < 30 ml/min
Pregnancy or breast feeding in patients who are prescribed a direct oral anticoagulant
Life expectancy of less than 3 months

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This trial seeks to evaluate a management strategy after the acute treatment duration (≥ 3 months of therapeutic anticoagulation) for patients with cancer and catheter-related upper extremity deep vein thrombosis (DVT).